… palivizumab during the 2000–2004 RSV seasons. We evaluated the characteristics of enrolled
registry subjects with congenital heart disease … these subjects collected in the 2002–2004 …

… , obtained from the British National FormularyCitation35, was based on the cost of a 100 mg
vial of palivizumab in the UK in 2004, which was $1360. To treat the cohort of 131 identified …

… 2000–2002 and 2004–2006 were used … Palivizumab Outcomes Registry (a voluntary report
system that does not include all CHD patients receiving palivizumab), the number of subjects …

… In another large, observational study by Cohen et al, after the initiation of palivizumab
prophylaxis, the respiratory syncytial virus hospitalization rate decreased significantly from 4.3% to …

… Palivizumab Outcomes Registry was established in 2000 to … RSV seasons (2000 to
2001 through 2003 to 2004) and is the … congenital heart disease. J Pediatr 2003; 143: 532–540. …

… (HSCHD), or immunocompromised individuals. … The results of the Palivizumab Outcomes
Registry conducted between 2000 and 2004 showed a very low rate of hospital admissions (1.9…

… , and 31% had congenital heart disease. The risk of serious … in these high-risk patients in
January 2004 [17]. Notably, the … Here we report results from the German Synagis Registry, a …

… -Ig in children with congenital heart disease because it was … according to standard growth
curves for 2000 g infants, and cost … was conducted between November 2004 and May 2006 in …

… lung disease of prematurity, and congenital heart disease (CHD… children who received
palivizumab from 2000 to 2004 (4 … with palivizumab and were able to meet project and subject …

… Palivizumab was available in 2000 and it is possible that … Cohen SA, Zanni R, Cohen A,
Harrington M, VanVeldhuisen … : results from the 20002004 Palivizumab Outcomes Registry. …